Pinometostat
- Generic Name
- Pinometostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H42N8O3
- CAS Number
- 1380288-87-8
- Unique Ingredient Identifier
- 8V9YR09EF3
- Background
Pinometostat has been used in trials studying the treatment of Leukemia, Acute Leukemias, Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Acute Lymphocytic Leukemia, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT03724084
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT03701295
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath